Managing Idiopathic Thrombocytopenic Purpura
This information was originally presented on September 15, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Identify the challenges associated with the diagnosis and management of ITP
- Discuss the first-line and second-line therapies for the management of ITP
- Outline the mechanism of action of recently approved thrombopoietic agents
- Summarize the data from clinical trials evaluating thrombopoietic agents for the treatment of refractory ITP
Eric H. Kraut, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
- 0.50 Participation
- 0.50 Nurse
- 0.50 Pharmacist
- 0.50 Physician